RACHEL STUCK: Open Payments
NPI 1154087781 · CRITTENDEN, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$982 in 60 payments from 20 companies in 2025. Trend: 2023 $205 · 2024 $590 · 2025 $982
Food & beverage: $982
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $186 |
| Vanda Pharmaceuticals Inc. | 8 | $158 |
| PFIZER INC. | 10 | $137 |
| Dexcom, Inc. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $53 |
| Lilly USA, LLC | 3 | $46 |
| Astellas Pharma US Inc | 2 | $41 |
| Corcept Therapeutics | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| Novo Nordisk Inc | 2 | $33 |
Products named: VRAYLAR, FANAPT, UBRELVY, HETLIOZ, NURTEC ODT, Dexcom G6 Transmitter, CAPLYTA, MOUNJARO.
Industry payments across KY — which companies pay providers there.
